⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115404 | 0.76 | — | — | |
| SCHEMBL15345998 | 0.68 | — | — | |
| SCHEMBL15849491 | 0.68 | — | — | |
| SCHEMBL179699 | 0.68 | — | — | |
| SCHEMBL123556 | 0.68 | — | — | |
| SCHEMBL16689075 | 0.64 | — | — | |
| SCHEMBL2442957 | 0.62 | — | — | |
| SCHEMBL13369649 | 0.60 | — | — | |
| SCHEMBL2313043 | 0.60 | — | — | |
| SCHEMBL11054195 | 0.59 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186239-B1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-10-10 | — | — | EP | claimed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | claimed |
| EP-3186239-A1 | ANTIRETROVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2017-07-05 | — | — | EP | claimed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | claimed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | claimed |
| WO-2016033243-A1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-03-03 | — | — | WO | claimed |
| US-20090203742-A1 | BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | SURLERAUX DOMINIQUE LOIS NESTO | 2009-08-13 | — | — | US | claimed |
| EP-1370543-B1 | BROADSPECTRUM 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARM LTD (IE) | 2006-10-25 | — | — | EP | claimed |
| US-20050267156-A1 | Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. | 2005-12-01 | — | — | US | claimed |
| EP-1545518-A1 | BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2005-06-29 | — | — | EP | claimed |
| US-20040116485-A1 | Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-06-17 | — | — | US | claimed |
| WO-2004014371-A1 | BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-02-19 | — | — | WO | claimed |
| EP-1370543-A2 | BROADSPECTRUM 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2003-12-17 | — | — | EP | claimed |
| WO-2002083657-A2 | BROADSPECTRUM 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2002-10-24 | — | — | WO | claimed |
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| WO-2021147697-A1 | SIDEROPHORE-DIHYDROFOLATE REDUCTASE INHIBITOR CONJUGATE AND APPLICATION THEREOF | 嘉圣生物医药(嘉兴)有限公司 | 2021-07-29 | — | — | WO | disclosed |
| EP-3823957-A1 | INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2021-05-26 | — | — | EP | disclosed |
| WO-2003049746-A2 | COMBINATION OF CYTOCHOME P450 DEPENDENT PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003049746-A2 | COMBINATION OF CYTOCHOME P450 DEPENDENT PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003039454-A2 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2003-05-15 | — | — | WO | disclosed |